Alirocumab clinical trials
Pro Research Analysisby 
Searched over 200M research papers
Alirocumab Clinical Trials: LDL-C Lowering Efficacy and Cardiovascular Outcomes
LDL-C Reduction in High-Risk Populations
Multiple large clinical trials have shown that alirocumab, a PCSK9 inhibitor, provides significant reductions in low-density lipoprotein cholesterol (LDL-C) for patients at high cardiovascular risk, including those with familial hypercholesterolemia. In pooled analyses of eight phase 3 ODYSSEY trials, alirocumab reduced LDL-C by about 49–60% compared to placebo or ezetimibe, with most patients achieving risk-based LDL-C goals at 24 weeks. These reductions were sustained for up to two years, and similar benefits were observed in both Western and Asian populations, including South Korea and Taiwan, where over 85% of patients reached LDL-C targets with alirocumab versus 14% with placebo Farnier2016Koh2017.
Dosing Flexibility and Monotherapy
Alirocumab has been tested at various dosing regimens. The ODYSSEY CHOICE I trial demonstrated that a 300 mg dose every four weeks, either as monotherapy or added to statins, led to LDL-C reductions of 53–59% at 24 weeks, with dose adjustments needed in a minority of patients. This supports the use of flexible dosing schedules to meet individual patient needs .
Efficacy in Homozygous Familial Hypercholesterolemia
In patients with homozygous familial hypercholesterolemia (HoFH), who typically have extremely high LDL-C and early cardiovascular disease, alirocumab reduced LDL-C by 36% compared to placebo at 12 weeks. Significant reductions were also seen in other atherogenic lipids, and the treatment was well tolerated .
Cardiovascular Event and Mortality Reduction
Major Adverse Cardiovascular Events (MACE) and All-Cause Mortality
Meta-analyses and the ODYSSEY OUTCOMES trial have shown that alirocumab reduces the risk of major adverse cardiovascular events (MACE) and all-cause mortality in patients with recent acute coronary syndrome. Alirocumab lowered the risk of total nonfatal cardiovascular events and deaths, with the total number of events prevented being twice the number of first events prevented. The reduction in all-cause mortality was significant, while the reduction in cardiovascular mortality alone did not reach statistical significance Goodman2023Wang2021Guedeney2019+2 MORE.
Legacy Effects of Short-Term Intensive LDL-C Lowering
A short period of very low LDL-C achieved with alirocumab plus statin, followed by statin alone, was associated with a persistent reduction in cardiovascular risk for several years, suggesting a legacy effect from intensive early LDL-C lowering .
Safety and Tolerability
Adverse Events and Neurocognitive Safety
Across trials, alirocumab was generally well tolerated. The most common side effects were mild, such as injection-site reactions and upper respiratory infections. Serious adverse events were similar between alirocumab and placebo groups. Importantly, there was no evidence of increased neurocognitive adverse events, even in patients achieving very low LDL-C levels, and no increased risk of liver enzyme elevations, rhabdomyolysis, or new-onset diabetes Farnier2016Koh2017Roth2016+4 MORE.
Conclusion
Alirocumab consistently lowers LDL-C and other atherogenic lipids in diverse high-risk populations, including those with familial hypercholesterolemia. It reduces the risk of major cardiovascular events and all-cause mortality, with a favorable safety profile and no significant increase in neurocognitive or other serious adverse events. Flexible dosing and sustained efficacy make alirocumab a valuable option for patients needing additional LDL-C lowering beyond statins.
Sources and full results
Most relevant research papers on this topic